$925.00
Free shipping on orders over $2,000
Price per pack (10 vials). Discount applies to this compound only – no mix and match.
| 10mg | ||
|---|---|---|
| Quantity | Price per Pack | Savings |
| 1 pack | $925 per pack | |
| 2 packs | $786 per pack | 15% off |
| 3 packs | $668 per pack | 28% off |
| 5 packs | $601 per pack | 35% off |
| 10 packs | $541 per pack | 42% off |
| 25 packs | $487 per pack | 47% off |
Survodutide (development code BI 456906) is a synthetic dual agonist targeting the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), co-developed by Boehringer Ingelheim and Zealand Pharma. It emerged from research programs exploring the complementary metabolic roles of glucagon and GLP-1 signaling in the liver and pancreas. Phase II clinical data published in 2023–2024 examined its effects in obesity and metabolic dysfunction-associated steatohepatitis (MASH). Unlike pure GLP-1R agonists such as semaglutide, survodutide’s GCGR component adds a hepatic fat oxidation and lipolytic dimension that has shown more pronounced visceral and hepatic fat reduction in preclinical and early clinical models. The molecule represents a mechanistic step beyond single-receptor incretin pharmacology.
GLP-1R agonism alone drives satiety and insulin secretion; GCGR agonism independently promotes hepatic fat oxidation and gluconeogenesis regulation. In combination, these pathways produce an additive reduction in body weight and liver fat accumulation that neither target achieves as efficiently in isolation. Survodutide’s specific GCGR:GLP-1R binding ratio has been tuned to minimize the hyperglycemic risk that full glucagon agonism would otherwise introduce, making it a pharmacologically balanced dual-receptor tool compound for metabolic research.
| Mechanism | Effect |
|---|---|
| GCGR agonism | Hepatic fat oxidation; increased lipolysis in adipose tissue; gluconeogenesis modulation |
| GLP-1R agonism | Glucose-dependent insulin secretion; gastric emptying delay; satiety signaling via vagal afferents |
| Dual GCGR/GLP-1R co-activation | Additive body weight reduction in rodent and non-human primate obesity models |
| Hepatic lipid clearance | Reduction in steatosis markers in MASH/NASH animal models; Phase II MASH data (2024) |
| cAMP signaling (both receptors) | Gs-coupled adenylyl cyclase activation → PKA-mediated downstream metabolic gene expression |
Survodutide is used in studies examining:
| Format | Lyophilized powder |
| Purity | ≥99% |
| Aliases | BI 456906, Survodutide |
| Available sizes | 10mg |
| Storage | 2–8°C unopened; stable 12+ months |
| Use | Research purposes only — not for human use |
Survodutide arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:
Total mg ÷ Volume added (mL) = Concentration (mg/mL)
Example: 10mg vial + 2mL BAC water = 5mg/mL solution
Reconstituted peptide should be stored at 2–8°C and used within 28–30 days.
Research frameworks for survodutide are drawn from published Phase II clinical protocols and preclinical dose-escalation studies. Human trials used a weekly subcutaneous dose-escalation design; animal studies employed weight-based subcutaneous dosing.
Survodutide is commonly paired in research settings with:
Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.
